These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 3698032

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26.
    van Laar JA, Durrani FA, Rustum YM.
    Cancer Res; 1993 Apr 01; 53(7):1560-4. PubMed ID: 8453623
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effects of PALA on the pharmacokinetics of 5-fluorouracil.
    Nassim MA, Rouini MR, Cripps MC, Shirazi FH, Veerasinghan S, Molepo JM, Obrocea M, Redmond D, Bates S, Fry D, Stewart DJ, Goel R.
    Oncol Rep; 1998 Apr 01; 5(1):217-21. PubMed ID: 9458325
    [Abstract] [Full Text] [Related]

  • 28. Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
    Wadler S, Gleissner B, Hilgenfeld RU, Thiel E, Haynes H, Kaleya R, Rozenblit A, Kreuser ED.
    Eur J Cancer; 1996 Jun 01; 32A(7):1254-6. PubMed ID: 8758262
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL.
    J Clin Oncol; 1990 Sep 01; 8(9):1497-503. PubMed ID: 2391557
    [Abstract] [Full Text] [Related]

  • 30. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 31. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.
    Eur J Cancer; 1994 Sep 04; 30A(7):950-5. PubMed ID: 7946590
    [Abstract] [Full Text] [Related]

  • 32. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
    Mann GB, Hortobagyi GN, Buzdar AU, Yap HY, Valdivieso M.
    Cancer; 1985 Sep 15; 56(6):1320-4. PubMed ID: 4027872
    [Abstract] [Full Text] [Related]

  • 33. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B, Singh G, Silberman H.
    J Clin Oncol; 1988 Jun 15; 6(6):1053-8. PubMed ID: 3373260
    [Abstract] [Full Text] [Related]

  • 34. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM, Anderson LW, Erlichman C, Cysyk RL.
    Cancer Res; 1980 Aug 15; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [Abstract] [Full Text] [Related]

  • 35. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL, Yee LK, Schuler B, Hamilton JM, Chen AP, Chabuk C, Grollman F, Grabenc M, Allegra CJ, Takimoto CH.
    Ann Oncol; 2001 Nov 15; 12(11):1581-7. PubMed ID: 11822758
    [Abstract] [Full Text] [Related]

  • 36. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS, Schutt AJ, Moertel CG, O'Connell MJ.
    Cancer Treat Rep; 1979 Nov 15; 63(11-12):1909-12. PubMed ID: 526923
    [Abstract] [Full Text] [Related]

  • 37. Growth inhibitory effect of N-(phosphonacetyl)-L-aspartic acid on human myeloid leukemia-derived cell lines and modulation by dipyridamole.
    Taguchi H, Kubonishi I, Miyoshi I.
    Anticancer Res; 1989 Nov 15; 9(4):845-8. PubMed ID: 2817812
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Harstrick A, Köhne CH, Hiddemann W, Preusser P, Strumberg D, Berns T, Seeber S, Wilke H, Schmoll HJ.
    Ann Oncol; 1997 Sep 15; 8(9):917-8. PubMed ID: 9358946
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.